Clinical Trial Update: Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 trial to assess the safety and early efficacy of an immune response modifier for inoperable advanced melanoma skin lesions. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Immune Response Modifier

Snippet

Sponsor: Pfizer | Conditions: Melanoma | Phase 1 | Status: COMPLETED